Quantity of qualified sufferers: CDEC reviewed the uncertainty in the volume of individuals with moderately serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are categorized as getting mild